This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Fostemsavir
  • /
  • Attachment Inhibitor Comparison in Heavily Treatme...
Clinical trial

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

Read time: 1 mins
Last updated:21st Sep 2020
Status: Active, not recruiting
Identifier: NCT02362503
Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.

Study Type: Interventional (Clinical Trial)
Actual Enrollment: 371 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of Fostemsavir (BMS-663068/GSK3684934) in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1 (BRIGHTE Study)
Actual Study Start Date: February 23, 2015
Actual Primary Completion Date: August 18, 2016
Estimated Study Completion Date: December 31, 2024

- Experimental: A1: BMS-663068
- Active Comparator: B1: Placebo + BMS-663068
- Experimental: BMS-663068

Category Value
Study type(s) Interventional
Expected enrolment 371
Study start date 23 February 2015
Estimated study completion date 31 December 2024

View full details